Cargando…

Effects of Adriamycin-Cytoxan chemotherapy on hematological and electrolyte parameters among breast cancer patients

BACKGROUND: Adriamycin-Cytoxan (AC) is a common chemotherapy treatment for breast cancer (BC) patients. Its electrolyte and hematological adverse effects have not been addressed adequately. OBJECTIVE: This study aimed to assess the effect of AC on hematological and electrolyte parameters among BC pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tadesse, Fikremariam Abiye, Leminie, Abebaye Aragaw
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185890/ https://www.ncbi.nlm.nih.gov/pubmed/37205205 http://dx.doi.org/10.3389/fonc.2023.1103013

Ejemplares similares

Catha edulis Forsk and Ascorbic Acid Effects on Hematological Indices in Rat
por: Leminie, Abebaye Aragaw, et al.
Publicado: (2021)

Determinants for perinatal adverse outcomes among pregnant women with preterm premature rupture of membrane: A prospective cohort study
por: Abebe, Tariku Abewa, et al.
Publicado: (2022)

Level of Acceptance of Illness and Its Association with Quality of Life among Patients with Epilepsy in North Shewa, Ethiopia
por: Teshome, Yonas, et al.
Publicado: (2022)

Effects of Catha Edulis Forsk on spatial learning, memory and correlation with serum electrolytes in wild-type male white albino rats
por: Limenie, Abebaye Aragaw, et al.
Publicado: (2022)

The Synergistic Effects of Pyrotinib Combined With Adriamycin on HER2-Positive Breast Cancer
por: Wang, Chaokun, et al.
Publicado: (2021)

Cyclodextrin Nanosponges Inclusion Compounds Associated with Gold Nanoparticles for Potential Application in the Photothermal Release of Melphalan and Cytoxan
por: Salazar, Sebastián, et al.
Publicado: (2021)

Radiation Synthesis of Selenium Nanoparticles Capped with β-Glucan and Its Immunostimulant Activity in Cytoxan-Induced Immunosuppressed Mice
por: Dung, Nguyen Thi, et al.
Publicado: (2021)

Prediction of bone metastasis risk of early breast cancer based on nomogram of clinicopathological characteristics and hematological parameters
por: Tian, Zhaokun, et al.
Publicado: (2023)

Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1
por: Pan, Xiaoping, et al.
Publicado: (2020)

Retraction: Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1
Publicado: (2021)

A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma.
por: Carmo-Pereira, J., et al.
Publicado: (1987)

A Nomogram Based on Hematological Parameters and Clinicopathological Characteristics for Predicting Local–Regional Recurrence After Breast-Conserving Therapy
por: Sun, Luhao, et al.
Publicado: (2022)

Analysis of Cardiac Adverse Reactions Caused by Different Doses of Adriamycin Chemotherapy in Patients with Breast Cancer
por: Hu, Guangwen, et al.
Publicado: (2022)

Comparison of neoadjuvant adriamycin and docetaxel versus adriamycin, cyclophosphamide followed by paclitaxel in patients with operable breast cancer
por: Hong, Woo Sung, et al.
Publicado: (2013)

Distribution Width of Red Blood Cells and Related Factors Among Patients with End-Stage Renal Disease in Addis Ababa, Ethiopia
por: Melese, Daniel Molla, et al.
Publicado: (2022)

Block sequential adriamycin CMF – optimal non-myeloablative chemotherapy for high risk adjuvant breast cancer?
por: Cameron, D A, et al.
Publicado: (2002)

Rewarding Effect of Catha edulis (Khat) and the Sex Differences to the Responses in Swiss Albino Mice
por: Limenie, Abebaye Aragaw, et al.
Publicado: (2020)

The cost-effectiveness of neoadjuvant chemotherapy in women with locally advanced breast cancer: Adriamycin and cyclophosphamide in comparison with paclitaxel and gemcitabine
por: Javan-Noughabi, Javad, et al.
Publicado: (2018)

Role of (18)FDG PET/CT metabolic parameters in predicting hematological toxicity during chemoradiotherapy for locally advanced cervical cancer
por: Meng, Tianyu, et al.
Publicado: (2022)

Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin
por: He, Ye, et al.
Publicado: (2015)

Metastatic Metaplastic Breast Cancer Successfully Treated with Adriamycin and Cisplatin
por: Hayashino, Kenta, et al.
Publicado: (2022)

Protective Effects of Sesamin on Cytoxan-Induced Spermatogenesis Dysfunction by Regulating RNF8-ubH2A/ubH2B Pathways in Male Mice
por: Hai, Dong-Mei, et al.
Publicado: (2021)

Advanced Stage Is a Risk for Severe Neutropenia in Breast Cancer Patients Undergoing Neoadjuvant Adriamycin/Cyclophosphamide/Docetaxel Chemotherapy
por: Moro, Kazuki, et al.
Publicado: (2022)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced Soft Tissue Sarcoma: A Pooled Analysis of Randomized Trials
por: Wang, Bi-Cheng, et al.
Publicado: (2021)

Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)

Chemotherapy-associated oral microbiome changes in breast cancer patients
por: Klymiuk, Ingeborg, et al.
Publicado: (2022)

Advances in Imaging in Evaluating the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer
por: Kong, Xianshu, et al.
Publicado: (2022)

Body composition change during neoadjuvant chemotherapy for breast cancer
por: Jang, Min Kyeong, et al.
Publicado: (2022)

Metabolic Syndrome Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
por: Lu, Ying, et al.
Publicado: (2022)

Electrolyte Disorders Induced by Antineoplastic Drugs
por: Verzicco, Ignazio, et al.
Publicado: (2020)

Breast-conserving surgery versus mastectomy for treatment of breast cancer after neoadjuvant chemotherapy
por: Song, Yu-Chun, et al.
Publicado: (2023)

Metabolomic approach to evaluating adriamycin pharmacodynamics and resistance in breast cancer cells
por: Cao, Bei, et al.
Publicado: (2013)

Dynamic Metabolic Response to Adriamycin-Induced Senescence in Breast Cancer Cells
por: You, Rong, et al.
Publicado: (2018)

Hematological Toxicities of Concurrent Chemoradiotherapies in Head and Neck Cancers: Comparison Among Cisplatin, Nedaplatin, Lobaplatin, and Nimotuzumab
por: Wu, Qiuji, et al.
Publicado: (2021)

Sphingosine 1-phosphate receptors and sphingosine kinase 1: novel biomarkers for clinical prognosis in breast, prostate, and hematological cancers
por: Pyne, Susan, et al.
Publicado: (2012)

Acute arterial thrombosis during adjuvant Adriamycin-cyclophosphamide chemotherapy in a patient with early breast cancer: A case report
por: Jang, Lee Chan, et al.
Publicado: (2019)

Global and Regional Longitudinal Strain Reduction in Breast Cancer Patients After First Chemotherapy Cycle With Fluorouracil, Adriamycin, and Cyclophosphamide Regimen
por: Astuti, Astri, et al.
Publicado: (2021)

IKKα inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis
por: Liao, Jian, et al.
Publicado: (2023)

Adriamycin-resistant cells are significantly less fit than adriamycin-sensitive cells in cervical cancer
por: Qi, Min, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h0varnguj7dt7a9fnqghhe1ics